Juncell Therapeutics is focused on innovative TIL (tumor-infiltrating lymphocyte) therapies for solid tumors, including both natural TIL programs and non-viral gene-modified TIL programs. Our TIL therapies are featured with an improved safety profile without compromising efficacy, thanks to the enhanced TIL manufactured by DeepTIL® cell expansion platform. DeepTIL® enables TIL to be potent enough so that the high-dose IL-2 combination could be eliminated and the intensity of pretreatment could be much lower. Juncell also established the NovaGMP® non-viral vector gene-modification platform, which is of high efficiency (> 45% in the final cell product) and low cost of goods (<10% of lentiviral vector). Juncell natural TIL therapy GC101 and gene-engineered TIL therapy GC203 have shown promising efficacy in melanoma, lung cancer, ovarian cancer, pancreatic cancer, cervical cancer, endometrial cancer, bile duct cancer, glioma and breast cancer.
Company Details
- Employees
- 2
- Founded
- 2019
- Address
- No. 28, Xiangle Road, Jiading District, Shanghai,shanghai 201802,china
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://www.juncell.com/en
- HQ
- Shanghai, Shanghai
Juncell Therapeutics Questions
Juncell Therapeutics's website is https://www.juncell.com/en
Juncell Therapeutics's LinkedIn profile is https://cn.linkedin.com/company/juncell-therapeutics
Juncell Therapeutics has
2 employees.
View email and phone details for 2
employees at Juncell Therapeutics.
Juncell Therapeutics's industry is
Biotechnology Research
Juncell Therapeutics's top competitors are
Sanyou Biopharmaceuticals,
Epimab Biotherapeutics, Inc.,
Jifeng Ventures 济峰资本,
Genestac Therapeutics,
Hualan Biological Engineering Inc.,
上海细胞治疗集团,
Laekna,
Iovance Biotherapeutics, Inc.,
上海君赛生物科技有限公司,
Grit Biotechnology.
Juncell Therapeutics's categories are Biotechnology Research
Juncell Therapeutics's founding year is 2019
